Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 5, 2013, Pages 578-584

  Gandhi, Monica ^a   Mwesigwa, Julia ^b   Aweeka, Francesca ^c   Plenty, Albert ^d   Charlebois, Edwin ^a,d   Ruel, Theodore D ^c   Huang, Yong ^c   Clark, Tamara ^a   Ades, Veronica ^c   Natureeba, Paul ^b   Luwedde, Flavia A ^b   Achan, Jane ^b   Kamya, Moses R ^b   Havlir, Diane V ^a   Cohan, Deborah ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Concentrations; Efavirenz; Hair plasma; HIV; Lopinavir ritonavir; Maternal to child transfer; Perinatal transmission

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; ZIDOVUDINE;

ANEMIA; ARTICLE; BACTERIAL INFECTION; BREAST FEEDING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HAIR LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; NEUTROPENIA; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; UGANDA;

ANTI-HIV AGENTS; BENZOXAZINES; FEMALE; HAIR; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; LOPINAVIR; MILK, HUMAN; PLASMA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RITONAVIR; UGANDA;

EID: 84883438216     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31829c48ad     Document Type: Article

References (36)

1. UNAIDS. Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. 2011. Available at: http://www.who.int/hiv/pub/me/monitoring-framework/en/index.html. Accessed February 5, 2013.
2. UNAIDS. Together we will end AIDS. 2012. Available at: http://www. unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/ 20120718-togetherwewillendaids-en.pdf. Accessed February 5, 2013.
3. WHO. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. 2012. Available at: http://www.who.int/hiv/ pub/mtct/programmatic-update2012/en/index.html. Accessed February 5, 2013.
4. Gray T, Huestis M. Bioanalytical procedures for monitoring in utero drug exposure. Anal Bioanal Chem. 2007;388:1455-1465.
5. Anderson GD. Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol. 2006;2:947-960.
6. Beumer J, Bosman I, Maes R. Hair as a biological specimen for therapeutic drug monitoring. Int J Clin Pract. 2001;55:353-357.
7. Gareri J, Koren G. Prenatal hair development: implications for drug exposure determination. Forensic Sci Int. 2010;196:27-31.
8. Gandhi M, Ameli N, Bacchetti P, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis. 2011;52:1267-1275.
9. Gandhi M, Ameli N, Bacchetti P, et al. Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS. 2009;23:471-478.
10. Gandhi M, Ameli N, Gange S, et al. Concentrations of efavirenz in hair correlate strongly with 24-hour intensive pharmacokinetic measurements and with virologic outcomes. Paper presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 17-20, 2010; San Francisco, CA; paper 604.
11. Gandhi M, Greenblatt RM, Bacchetti P, et al. A single-nucleotide polymorphism in CYP2B6 leads to .3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis. 2012; 206:1453-1461.
12. van Zyl GU, van Mens TE, McIlleron H, et al. Low lopinavir plasma or hair concentrations explain second line protease inhibitor failures in a resourcelimited setting. J Acquir Immune Defic Syndr. 2011;56:333-339.
13. Huang Y, Gandhi M, Greenblatt RM, et al. Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22:3401-3409.
14. Huang Y, Yang Q, Yoon K, et al. Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2011;401: 1923-1933.
15. Achan J, Kakuru A, Ikilezi G, et al. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med. 2012;367: 2110-2118.
16. DAIDS Grading Scale. Division of AIDS table for grading the severity of adult and pediatric adverse events. Version 1.0, December 2004; Clarification August 2009. Available at: http://www.scribd.com/doc/57431404/DAIDS-Grading- Scale. Accessed February 5, 2013.
17. Chi J, Jayewardene AL, Stone JA, et al. Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS. J Pharm Biomed Anal. 2002;30:675-684.
18. Villani P, Feroggio M, Gianelli L, et al. Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography-mass spectrometry assay. Ther Drug Monit. 2001;23: 380-388.
19. Keil K, Frerichs VA, DiFrancesco R, et al. Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. Ther Drug Monit. 2003;25:340-346.
20. Ivanovic J, Nicastri E, Anceschi MM, et al. Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. Curr HIV Res. 2009;7:620-625.
21. Marzolini C, Rudin C, Decosterd LA, et al. Transplacental passage of protease inhibitors at delivery. AIDS. 2002;16:889-893.
22. Gingelmaier A, Kurowski M, Kastner R, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS. 2006;20:1737-1743.
23. van Hoog S, Boer K, Nellen J, et al. Transplacental passage of nevirapine, nelfinavir and lopinavir. Neth J Med. 2012;70:102-103.
24. Gavard L, Gil S, Peytavin G, et al. Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am J Obstet Gynecol. 2006;195:296-301.
25. Ceccaldi PF, Gavard L,Mandelbrot L, et al. Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model. Obstet Gynecol Int. 2009;2009:726593.
26. Fayet-Mello A, Buclin T, Guignard N, et al. Free and total plasma levels of lopinavir during pregnancy, at delivery and in postpartum: implication for dosage adjustments in pregnant women. Antivir Ther. 2013;18:171-182.
27. Kiser J, Mawhinney S, Kinzie K, et al. Total and unbound lopinavir/ritonavir pharmacokinetics in a concentration-guided study of HIV-infected women throughout pregnancy and post-partum. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada; paper #946.
28. Corbett A, Martinson F, Rezk N, et al. Lopinavir/ritonavir concentrations in breast milk and breast-feeding infants. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada; paper 947.
29. Rezk NL, White N, Bridges AS, et al. Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications. Ther Drug Monit. 2008;30:611-619.
30. Palombi L, Pirillo MF, Andreotti M, et al. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther. 2012;17:1511-1519.
31. Cressey TR, Stek A, Capparelli E, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr. 2012;59:245-252.
32. Schneider S, Peltier A, Gras A, et al. Efavirenz in human breast milk, mothers', and newborns' plasma. J Acquir Immune Defic Syndr. 2008;48:450-454.
33. Mayaux MJ, Dussaix E, Isopet J, et al. Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies. SEROGEST Cohort Group. J Infect Dis. 1997;175:172-175.
34. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med. 2011;8:e1000430.
35. Persaud D, Gay H, Ziemniak C, et al. Functional HIV cure after very early ART of an infected infant. Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Atlanta, GA; paper #48LB.
36. ter Heine R, Beijnen JH, Huitema AD. Bioanalytical issues in patientfriendly sampling methods for therapeutic drug monitoring: focus on antiretroviral drugs. Bioanalysis. 2009;1:1329-1338.